Efficacy of the anti-VZV (anti-HSV3) vaccine in HSV1 and HSV2 recurrent herpes simplex disease: A prospective study

Open Access Journal of Clinical Trials

Volumn 4, Issue , 2012, Pages 51-58

  Le Goaster, Jacqueline ^a   Gonzalo, Sylvie ^b   Bourée, Patrice ^a   Tangy, Frederic ^c   Haenni, Anne Lise ^d  

^a BICÊTRE HOSPITAL   (France)

^b Biomnis Laboratory   (France)

^c CNRS   (France)

^d INSTITUT JACQUES MONOD   (France)

Author keywords

Anti VZV (HSV3) vaccine; Anti VZV vaccine therapy; HSV1 HSV2 herpes prevention

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; MALE; MOLECULAR PHYLOGENY; PHYLOGENETIC TREE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; RECURRENT VIRUS INFECTION; SEROLOGY; TREATMENT OUTCOME;

EID: 84878376347     PISSN: None     EISSN: 11791519     Source Type: Journal    
DOI: 10.2147/OAJCT.S33292     Document Type: Article

References (17)

1. McGeoch DJ, Dolan A, Ralph AC. Toward a comprehensive phylogeny for mammalian and avian herpes viruses. J Virol. 2000;74:10401-10406.
2. Davison AJ, Eberle R, Ehlers B, et al. The order Herpesvirales. Arch Virol. 2009;154:171-177.
3. McGeoch DJ, Rixon FJ, Davison AJ. Topics in herpesvirus genomics and evolution. Virus Res. 2006;117:90-104.
4. Favoreel HW.Immune evasion of alpha herpes viruses. Verh K Acad Geneeskd Belg. 2008;701:47-65. Dutch.
5. Giehl KA, Müller-Sander E, Rottenkolber M, Degitz K, Volkenandt M, Berking C. Identification and characterization of 20 immunocompetent patients with simultaneous varicella zoster and herpes simplex virus infection. J Eur Acad Dermatol Venereol. 2008;22:722-728.
6. Schmidt NJ, Lennette EH, Magoffin RL. Immunological relationship between herpes simplex and varicella-zoster viruses demonstrated by complement-fixation, neutralization and fluorescent antibody tests. J Gen Virol. 1969;4:321-328.
7. Sadaoka K, Okamoto S, Gomi Y, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis. 2008;198:1327-1333.
8. Gershon AA, Katz SL. Perspective on live varicella vaccine. J Infect Dis. 2008;197 Suppl 2:S242-S245.
9. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122:e744-e751.
10. Sauerbrei A, Färber I, Brandstädt A, Schacke M, Wutzler P. Immunofluorescence test for highly sensitive detection of varicellazoster-virus specific IgG - alternative to fluorescent antibody to membrane antigen test. J Virol Methods. 2004;119:25-30.
11. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospitals. Lancet. 1974;2:1288-1290.
12. Takahashi M. Current status and prospects of live varicella vaccine. Vaccine. 1992;10:1007-1014.
13. Kockler DR, McCarthy MW. Zoster vaccines live. Pharmacotherapy. 2007;27:1013-1019.
14. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis. 2008;197 Suppl 2: S165-S169.
15. Fife KH, Warren TJ, Justus SE, Heitman CK. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Sex Transm Dis. 2008;35:668-673.
16. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med. 2008;59:381-395.
17. Ferenczy MW. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. Curr Pharm Des. 2007;13:1975-1988.